Abstract
Codeletion of BRCA2 and RB1 increases prostate cancer sensitivity to PARP inhibitor therapy.
- Copyright © 2020, American Association for the Advancement of Science
Codeletion of BRCA2 and RB1 increases prostate cancer sensitivity to PARP inhibitor therapy.